GALAPAGOS AND HIGH Q FORM TARGET DISCOVERY ALLIANCE

The High Q Foundation and Galapagos announced that they have reached agreement in principle for a two-year target discovery alliance.

The organizations will apply Galapagos' adenoviral siRNA and cDNA collections and expertise in biology driven target discovery and validation of novel drug targets for the development of new Huntington Disease therapies. Galadeno, Galapagos' partnering unit, will perform the research in this collaboration.